ストックスクリーナーアプリを入手
154.27
9.93%
13.93
アフターアワーズ：
151.85
-2.42
-1.57%
前日終値:
$140.34
開ける：
$140.25
24時間の取引高:
25.71M
Relative Volume:
2.15
時価総額：
$61.59B
収益：
$2.23B
当期純損益:
$-3.19B
株価収益率:
-18.94
EPS:
-8.1462
ネットキャッシュフロー:
$-1.60B
1週間 パフォーマンス:
-2.87%
1か月 パフォーマンス:
+181.41%
6か月 パフォーマンス:
+187.98%
1年 パフォーマンス:
+540.39%
1日の値動き範囲:
$138.09
$154.70
1週間の範囲:
$133.33
$156.13
52週間の値動き範囲:
$22.28
$176.66
Moderna Inc Stock (MRNA) Company Profile
Compare MRNA vs VRTX, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
154.27 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
547.65 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
823.82 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,028.51 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
209.87 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Equal Weight |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-12 | 開始されました | Jefferies | Hold |
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Moderna cancer vaccine breakthrough revives hopes for biotech turnaround By Investing.com - Investing.com Nigeria
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology - Stocktwits
Health Care Up as Moderna Leads Biotech HigherHealth Care Roundup - marketscreener.com
Moderna Shares (NASDAQ:MRNA) Finish Landmark Week, Surging 70% Over Wall Street Consensus - TechStock²
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Yahoo Finance
Moderna Soars 129% for the Week | Closing Bell - marketscreener.com
Moderna Stock Erupts As Cancer Vaccine Trial Delivers Historic Win - StocksToTrade
Moderna Stock Explodes As Phase 3 Cancer Vaccine Data Hits - timothysykes.com
Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today’s Market - Barron's
Bessent's Bond Rescue, Bitcoin's Best Week Since 2023Coinbase Global (NASDAQ:COIN) - Benzinga
Moderna (MRNA) Cancer Vaccine Success Won’t Lift All mRNA Stocks - Barron's
Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet. - Barchart.com
Moderna’s Cancer Vaccine Breakthrough Sends Stocks Soaring - cheddar.com
Why Moderna’s mRNA Cancer Drug Hype Has Gone Too Far - Barron's
If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now - TradingView
Moderna Stock Explodes As Landmark Cancer Trial Sparks Re‑Rating - StocksToTrade
Moderna Stock Explodes After Landmark Cancer Vaccine Breakthrough - timothysykes.com
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink - WSJ
Moderna (NASDAQ:MRNA) Price Target Raised to $77.00 at JPMorgan Chase & Co. - MarketBeat
After Moderna’s Big News, Here Are Three Biotechs to Watch - TheStreet Pro
Moderna Inc Stock (MRNA) Moved Up by 14.01% on Aug 21: What Signal Does It Send? - TradingKey
Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Moderna jumps 18% on investor optimism - Breakingthenews.net
Moderna Options Flash Extreme Caution as Cancer Vaccine Fuels Stock Surge: Options Chatter - Moomoo
Moderna Cancer Vaccine Could Redefine the CompanyModerna (NASDAQ:MRNA) - Benzinga
Moderna (NASDAQ:MRNA) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
Merck & Co Inc Stock (MRK) Moved Up by 3.41% on Aug 21: Facts Behind the Movement - TradingKey
Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session - Yahoo Finance
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod - Pharma Voice
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning in trial - KXAN Austin
Rx Rundown: Moderna, Merck, LEO Pharma and more - Medical Marketing and Media
Moderna’s 177% Surge Has Investors Asking What Comes Next - MarketBeat
Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped - MarketWatch
Moderna and Merck cancer vaccine success paves way for future - EMJ
Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’ - Yahoo Finance
Meeder Advisory Services Inc. Buys New Shares in Moderna, Inc. $MRNA - MarketBeat
MEXC Lists Ondo Tokenized Stock Moderna (MRNAON), Expanding Access to U.S. Biotech Exposure - TradingView
A Cancer Vaccine Is Closer Than Ever - Bloomberg.com
Amid the chip bear market, healthcare is breaking out: Chart of the Day - Yahoo Finance
JPMorgan Adjusts Price Target on Moderna to $77 From $40, Keeps Underweight Rating - marketscreener.com
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED) - Yahoo Finance
Personalized cancer vaccine launched by Moderna: Drug firm’s shares soar more than 100% — should you buy? - Yahoo! Finance Canada
Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Holdings in Moderna, Inc. $MRNA - MarketBeat
983,450 Shares in Moderna, Inc. $MRNA Bought by Deutsche Bank AG - MarketBeat
Moderna (MRNA) Clears A Phase 3 Milestone, Is The Upside Already Priced In? - Yahoo Finance
5 Reasons Why Moderna Stock Jumped 170% and How Far It Can Go - CryptoRank
Watch Moderna, Merck Cancer Vax Gives Hope - Bloomberg.com
Moderna, Merck develop vaccine that could help fight against melanoma - cbs8.com
Moderna (MRNA) Sees Stock Surge After Positive Melanoma Trial Re - GuruFocus
FDA approves Moderna's mRNA seasonal flu vaccineABC News - ABC News - Breaking News, Latest News and Videos
Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead - Yahoo Finance
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
Moderna Inc (MRNA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bancel Stephane | Chief Executive Officer |
Aug 06 '26 |
Option Exercise |
19.15 |
252,469 |
4,834,781 |
6,440,260 |
| Bancel Stephane | Chief Executive Officer |
Aug 05 '26 |
Sale |
57.52 |
499,246 |
28,715,011 |
6,187,791 |
0.31%
2.09%
大文字化:
|
ボリューム (24 時間):